WEBi 50: Making New Vaccines Work: Strategies for Introduction, Delivery, and Demand – Example of RSV

Value of the Information & Strength of the Argument

The webinar provides valuable information on RSV prevention, particularly the introduction of maternal vaccines and monoclonal antibodies. The argumentation is solid, based on data from clinical trials and real-world implementation in the Americas. The speakers present evidence for vaccine efficacy and effectiveness, and discuss practical challenges such as cost and logistics. The content is well-structured, with clear explanations of strategies and considerations for different settings.

Scientific Rigor, Source Quality, Title Accuracy

The webinar demonstrates scientific rigor by referencing peer-reviewed studies, WHO position papers, and PAHO recommendations. The sources are credible and relevant. The title accurately reflects the content, focusing on strategies for vaccine introduction and delivery using RSV as an example. The presentation is consistent with current scientific consensus and provides practical guidance for public health professionals.

The title accurately reflects the content, which focuses on strategies for introducing and delivering new vaccines, using RSV as a case study.

8/10

The webinar features experts from WHO/PAHO and academic institutions, presenting data from peer-reviewed studies and official surveillance. The content is consistent with current scientific consensus, though it relies on expert opinion and programmatic experience rather than original research.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by Dr. Ziad Memish, outlining webinar objectives and introducing speakers.
• 05:00Dr. Francisco Nogareda presents global epidemiology of RSV and PAHO recommendations.
• 10:00Discussion on introduction of maternal vaccine and monoclonal antibodies in the Americas.
• 15:00Implementation considerations: timing, safety monitoring, and integration into health systems.
• 20:00Challenges: high cost, short vaccination window, and need for surveillance.
• 25:00Q&A session addressing applicability to low-income and conflict settings.
• 30:00Dr. Muhammad Imran Nisar presents burden of RSV in LMICs and importance of maternal immunization.
• 35:00Evidence from MATISSE trial: efficacy and safety of RSV vaccine.
• 40:00Discussion on hidden mortality and underestimation of RSV burden.
• 45:00Conclusion and final remarks.

• PAHO Revolving Fund — Mentioned as a mechanism for procuring vaccines at lower cost in the Americas.
• WHO Position Paper on RSV — Referenced as the May 2025 WHO position paper on RSV prevention.
• MATISSE trial — Cited as the phase 3 trial of the RSV maternal vaccine.
• Lancet study on impact in Chile — Mentioned as a study evaluating the impact of RSV prevention in Chile.

• WHO RSV fact sheet — Provides global burden and prevention information consistent with the webinar.
• CDC RSV information — Offers information on RSV vaccines and monoclonal antibodies, supporting the webinar's content.